ClinicalTrials.gg
CompletedNCT01701232Updated Nov 6, 2017

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

A Phase 3 interventional study of rituximab in Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma and Splenic Marginal Zone Lymphoma, sponsored by Biocad. Completed at 62 sites in 5 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2017-11-06.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
36th of 188
174 · median 48
Started
2011
with 8 others
Phase 3
35 of 194
2 open now
Registered
142nd of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 36th largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2011, is one of 35 in phase 3, and was the 142nd registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This international multi-center, randomized, controlled, open-label study investigated the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (INN: rituximab, CJSC Biocad) versus MabThera® (INN: rituximab, F. Hoffmann La Roche, Ltd.) both administered as a monotherapy of patients with indolent non-Hodgkin's lymphoma.

Patients were randomized to receive 375 mg/m² BCD-020 as intravenous infusion once a week for 4 weeks or MabThera® at the same regimen.

03

Conditions studied

  • Follicular Non-Hodgkin's Lymphoma
  • Nodal Marginal Zone Lymphoma
  • Splenic Marginal Zone Lymphoma

Keywords

  • lymphoma, non-Hodgkin's
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having signed a written ;
  • Patients' age is 18 years or more;
  • Diagnosis of CD20-positive indolent non-Hodgkin lymphoma of following morphological types:Follicular non-Hodgkin lymphoma stage II-IV according to Ann Arbor, grade I-II;Nodal marginal zone lymphoma stage II-IV according to Ann Arbor; Splenic marginal zone lymphoma.
  • of not less than 3 months after the enrollment in the study;
  • Morphological and immunohistochemical examination of the tumor (both lymph node and bone marrow biopsy) - within 3 months before the enrollment in the study ;
  • Performance status ≤2 on the scale;
  • > 80 g/l; leukocyte count ≥ 3.0×109/l but less than 25×109/l, ≥1.5×109/l, count ≥100×109/l;
  • Presence of at least one ;
  • Patient's ability in the investigator's opinion to comply with the protocol procedures;
  • Willingness of patients with preserved reproductive function to use reliable methods (at least two contraception methods in women, e.g., spermicide and condom).

Exclusion criteria

Exclusion Criteria:

  • Bulky disease - size of any single lesion more than 10 cm in the greatest diameter;
  • Secondary transformation to high-grade lymphoma;
  • Other types of non-Hodgkin lymphomas apart from follicular non-Hodgkin stage II-IV lymphoma according to Ann Arbor, grade 1,2; nodal marginal zone lymphoma stage II-IV according to Ann Arbor; splenic marginal zone lymphoma.
  • Patients regularly taking during 1 month preceding the enrollment in the study;
  • Occurrence of other (aside from NHL) diseases that can distort the assessment of the main disease symptoms expression; mask, enhance, modify the main disease symptoms or induce clinical and laboratory-instrumental symptoms similar to the non-Hodgkin lymphomas; Severe resistant hypertension; Decompensated forms of heart ( class ХСН III, IV), liver and kidney disorders (creatinine level >133 µmol/l, , ALT, and level 3 times exceeding the norm) except for the cases where the symptom is caused by lymphoma; Decompensated respiratory failure; Tumor infiltration of the lungs; Decompensated diabetes mellitus; Active diseases; Ongoing infections requiring antimicrobial therapy.
  • Usage of the drugs:

At any time prior to the enrollment into the study - interferon-based drugs or monoclonal antibodies for the treatment of NHL; Chemotherapy or radiotherapy was completed less than 21 day prior to the enrollment into the study; Vaccination within 1 week prior to the enrollment into the study;

  • Presence of any psychiatric disorders including major depressive conditions and/or suicidal thoughts in anamnesis that in opinion of the investigator may put a patient at an excessive risk or influence the ability of patients to fulfill the study protocol;
  • Myocardial infarction less than 1 month before the enrollment into the study;
  • Severe CNS or PNS dysfunctions;
  • Drug and alcohol addiction;
  • Known , , infection, syphilis;
  • Known primary or secondary immunodeficiency;
  • Primary CNS lymphoma or in the CNS;
  • Known intolerance or allergy to mouse proteins or any components of the study drugs, and also to the premedication drugs;
  • Pregnancy or lactation;
  • Prior or concomitant malignances except for adequately treated basal cell carcinoma and in situ cervical cancer;
  • Any restraints or impossibility to administer the study drug via an intravenous infusion;
  • Major surgery within 1 week prior to the enrollment into the study;
  • Simultaneous participation in any other clinical study or any preceding participation in other studies within 3 months prior to enrollment in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Active comparator
    MabThera

    Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)

    Biological: rituximab

  • Experimental
    BCD-020

    Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)

    Biological: rituximab

Interventions

  • Biologicalrituximab

    Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)

    Also known as: Biological: BCD-020, MabThera

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Estimation of the overall response rate in each treatment arm at the end of treatment

    Time frame: day 50 (cycle 4)

  2. CD20-positive cells count

    Comparison of peripheral blood B-cell depletion and repletion after BCD-020 and MabThera intravenous administration

    Time frame: day 50

Secondary outcomes

  1. Cmax

    Estimation of maximum rituximab serum concentrations after administration of BCD-020 to that obtained after administration of MabThera

    Time frame: day 22

  2. AUC(0-168)

    Estimation of rituximab exposition after administration of BCD-020 to that obtained after administration of MabThera

    Time frame: 168 hours

  3. Complete response rate

    Assessment of complete response rates of BCD-020 and MabThera given as a monotherapy at the end/completion of the treatment

    Time frame: day 50

  4. Frequency of AEs/sAEs grade 3-4 (CTCAE v.4.03)

    Evaluation of the safety profiles of BCD-020 and MabThera

    Time frame: day 50

  5. Levels of binding and neutralizing antibodies to rituximab

    Immunogenicity assessment of BCD-020 and MabThera

    Time frame: day 50

  6. AUC(0-1176), AUC(0-inf)

    Estimation of rituximab serum concentrations after administration of BCD-020 to that obtained after administration of MabThera

    Time frame: day 50

07

Study locations

62 sites
  • Instituto Nacional de Cancerología
    Bogotá, Colombia
  • Fundación Reina Isabel
    Cali, Colombia
  • Hospital Pablo Tobon Uribe
    Medellín, Colombia
  • HCG Multi Specialty Hospitals
    Ahmedabad, 380006, India
  • Department of Medical Oncology, Navneet Memorial Hospital, "Sushrusha"
    Ahmedabad, 380009, India
  • Sujan Surgicals
    Amaravati, India
  • HCG Bangalore Institute of Oncology
    Bangalore, 560027, India
  • Department of Medicine (Haemotology), St.John's Medical College Hospital
    Bangalore, 560034, India
  • Narayana Hrudayalaya Hospitals
    Bangalore, 560099, India
  • Srinivasam Cancer Care Hospital
    Bangalore, India
  • All India Institute of medical Sciences (AIIMS)
    Bhubaneswar, India
  • Acharya Tulasi Regional Cancer Treatment and Research Centre
    Bikaner, India
  • G.Kuppuswamy Naidu Memorial Hospital
    Coimbatore, 641037, India
  • Medical Oncology Department, The Karnatak Cancer Therapy and Research Institute
    Hubli, 580025, India
  • BIBI General hospital & cancer center
    Hyderabad, 500024, India
  • Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute
    Hyderabad, 500034, India
  • Omega Hospitals
    Hyderabad, 500034, India
  • Nilratan Siracar Medical College & Hospital
    Kolkata, India
  • King George Medical University
    Lucknow, India
  • Department of Radiation Oncology, Meenakshi Mission Hospital & Research Centre
    Madurai, 625107, India
  • Manas Super Speciality Hospital
    Nashik, India
  • City Cancer Center
    Vijayawada, India
  • Arkhangelsk District Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • City Hospital N8
    Barnaul, 656010, Russian Federation
  • Municipal Institution "Central City Hospital № 7"
    Ekaterinburg, 620137, Russian Federation
  • Public health facility "Irkutsk Regional Oncology Center"
    Irkutsk, 664035, Russian Federation
  • Ivanovo Regional Oncology Center
    Ivanovo, 153013, Russian Federation
  • State Health Care Institution "Republican Clinical Cancer Center," the Ministry of Health of the Udmurt Republic
    Izhevsk, 426009, Russian Federation
  • Public health facility "Kemerovo Regional Hospital"
    Kemerovo, 650066, Russian Federation
  • Clinical Oncology Dispensary N1
    Krasnodar, 350040, Russian Federation
  • Public health facility "Kursk Regional Cancer Center," Health Committee of Kursk region
    Kursk, 305035, Russian Federation
  • Public health facility "Lipetsk Regional Oncology Center"
    Lipetsk, 398005, Russian Federation
  • N.N. Burdenko General Military Clinical Hospital
    Moscow, 105229, Russian Federation
  • Russian Medical Academy of Post-Graduate Education, Ministry of Health and Social Development of the Russian Federation
    Moscow, 123995, Russian Federation
  • Research Center for Hematology MHSD RF
    Moscow, 125167, Russian Federation
  • Official body of the health of the city of Moscow "Moscow City Clinical Hospital named after S. P. Botkin"
    Moscow, 125284, Russian Federation
  • Medical Radiological Research Center, Ministry of Health and Social Development of the Russian Federation
    Obninsk, 249036, Russian Federation
  • Regional government health care "Oryol Regional Hospital"
    Oryol, 302028, Russian Federation
  • Perm Region Oncology Dispensary
    Perm, 614066, Russian Federation
  • V.A. Baranov Republican Hospital of Ministry of Health republic Karelia
    Petrozavodsk, 185000, Russian Federation
  • Pyatigorsk Oncology Center
    Pyatigorsk, 357502, Russian Federation
  • Russian Research Institute of Hematology and Transfusiology Federal State Institution of Federal Medical and Biological Agency
    Saint Petersburg, 191024, Russian Federation
  • St. Petersburg State Health Care Institution "Alexander City Hospital"
    Saint Petersburg, 193312, Russian Federation
  • Saint Petersburg City Clinical Oncology Center
    Saint Petersburg, 197022, Russian Federation
  • Saint Petersburg Pavlov State Medical University
    Saint Petersburg, 197022, Russian Federation
  • V.A. Almazov Federal Center for Heart, Blood and Endocrinology, Ministry of Health and Social Development of the Russian Federation
    Saint Petersburg, 197341, Russian Federation
  • The federal government military educational institution of higher education, "Military Medical Academy named after SM Kirov's' Ministry of Defense"
    Saint Petersurg, 194044, Russian Federation
  • Provincial health official body "Smolensk Regional Clinical Oncological Dispensary"
    Smolensk, 214000, Russian Federation
  • Oncology Dispensary 2
    Sochi, 354057, Russian Federation
  • N.N.Petrov Oncology Research Center
    St.Petersburg, 197758, Russian Federation
  • Russian scientific center of radiology and surgery technologies
    St.Petersburg, Russian Federation
  • Tambov Regional Oncology Center
    Tambov, 390013, Russian Federation
  • Municipal Health "Clinical Hospital № 5" Togliatti
    Togliatti, 445846, Russian Federation
  • Tula Regional Hospital
    Tula, 300053, Russian Federation
  • Public health care setting of the Tyumen region "Regional Oncology Center"
    Tyumen, 625041, Russian Federation
  • State Health Care Institution Republican Clinical Hospital named after G. G. Kuvatova
    Ufa, 450005, Russian Federation
  • Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan
    Ufa, 450054, Russian Federation
  • Volgograd District Oncology Dispensary №1
    Volgograd, 400138, Russian Federation
  • Medi-Clinic Vereeniging
    Vereeniging, South Africa
  • Khmel'nyts'kyy Regional Hospital, Hematology Department
    Khmel'nyts'kyy, 29000, Ukraine
  • National Cancer Institute of Ukraine, Oncohematology Department
    Kiev, 03022, Ukraine
  • State Institution "Institute of Blood Pathology and Transfusion Medicine AMS of Ukraine", Hematology Department
    L'viv, 79044, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2012
First posted
Oct 5, 2012
Start
Sep 2011
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Last update
Nov 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01701232
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Oct 5, 2012
Start date
Sep 2011
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Nov 6, 2017

Study contacts

Roman Ivanov, PhD,MD
study director · CJSC Biocad

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion